ArticleAdvances in therapy2026
Associations of Mean Corpuscular Hemoglobin with Survival and Cardiovascular Outcomes Among Patients with Hemodialysis in Japan Based on Real-World Data.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnemia in chronic kidney disease increases mortality risk in patients with hemodialysis. Hemoglobin (Hb) is currently used as the primary biomarker for renal anemia management. Recently, mean corpuscular hemoglobin (MCH) has gained attention as an indicator for improving anemia care. Using a large real-world dataset, we assessed the associations of MCH with survival and cardiovascular outcomes in Japanese patients with hemodialysis.
methodsWe conducted a retrospective cohort study of 8266 patients receiving maintenance hemodialysis, using a nationwide electronic medical record database (Sept 2004-Apr 2023). MCH at the index date was categorized into quintiles. We examined the associations of MCH with all-cause mortality and major adverse cardiovascular events (MACE)-plus (comprising death, myocardial infarction, stroke, heart failure hospitalization, thromboembolism) using Cox proportional hazards models and restricted cubic spline analyses.
resultsOver a median follow-up of 2.8 years, 1414 deaths (17.1%) and 3537 MACE-plus events (42.9%) occurred. Low MCH (< 28.1 pg) was independently associated with increased all-cause mortality (adjusted hazard ratio [HR] 1.287; 95% confidence interval [CI] 1.012-1.637), while only a non-significant trend was observed for MACE-plus (p = 0.074). Spline analyses revealed that both low and high MCH were associated with increased mortality and MACE-plus. In patients with Hb 10.0-12.0 g/dL, low MCH (< 28.1 pg) was significantly linked to higher mortality (adjusted HR 1.432; 95% CI 1.007-2.038).
conclusionIn Japanese patients with hemodialysis, both low and high MCH levels may provide information for predicting mortality and cardiovascular risk. Incorporating MCH alongside Hb may enhance risk stratification and improve anemia management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.